Tag: FDA clozapine
REMS for Clozapine: ANC Monitoring and Safety Enrollment Changes in 2025
As of February 2025, the FDA removed the mandatory REMS program for clozapine, eliminating strict ANC monitoring requirements. While blood tests are still recommended, patients now face fewer barriers to accessing this highly effective treatment for treatment-resistant schizophrenia.
Read More